Related Experiment Video
Updated: May 10, 2026
A Murine Closed-chest Model of Myocardial Ischemia and Reperfusion
Published on: July 17, 2012
Matrix metalloproteinase-2 is activated during ischemia/reperfusion in a model of myocardial infarction
Virgilio J J Cadete1, Steven A Arcand, Bradley M Chaharyn
1Department of Pharmacology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Background:
The degradation of myosin light chain 1 (MLC1) by matrix metalloproteinase-2 (MMP-2) during ischemia/reperfusion has been implicated in the development of cardiac dysfunction. Our objective was to elucidate the role of MMP-2 and MLC1 in the development of cardiac injury and dysfunction in a model of left anterior descending (LAD) coronary artery occlusion.
Methods:
Adult rats (300-350 g) were anaesthetized, and the isolated hearts were retrogradely perfused in a Langendorff apparatus. The LAD was stabilized for 25 minutes and occluded for either 45 or 90 minutes and then reperfused. Cardiac function (evaluated as rate-pressure product) was significantly decreased in the reperfused hearts subjected to 90 minutes of LAD occlusion in comparison with hearts subjected to either sham or 45 minutes of occlusion. Ninety minutes of occlusion resulted in 60% of infarct.
Results:
MMP-2 activity, measured by gelatin zymography, was significantly increased following occlusion as well as reperfusion. An increased degradation of MLC1 was observed at the end of reperfusion, but not at the end of occlusion, which most likely was because of the compensatory increase in tissue inhibitor of matrix metalloproteinases-4 (TIMP-4) during occlusion, but not reperfusion.
Conclusion:
We demonstrate that MMP-2 activation is an ischemic event that extends into the reperfusion phase, while MLC1 degradation in response to ischemia/reperfusion is strictly a reperfusion event. MLC1 degradation during occlusion is prevented by a compensatory increase in the levels of TIMP-4.
Insights
Matrix metalloproteinase-2 (MMP-2) activation during ischemia extends into reperfusion, leading to myosin light chain 1 (MLC1) degradation. This MLC1 degradation is a reperfusion event, prevented during occlusion by tissue inhibitor of matrix metalloproteinases-4 (TIMP-4).
Area of Science:
- Cardiovascular Physiology
- Biochemistry
- Molecular Cardiology
Background:
- Myosin light chain 1 (MLC1) degradation by matrix metalloproteinase-2 (MMP-2) is linked to cardiac dysfunction following ischemia/reperfusion injury.
- Understanding the precise roles of MMP-2 and MLC1 in ischemia/reperfusion-induced cardiac injury is crucial for developing therapeutic strategies.
Purpose of the Study:
- To investigate the role of MMP-2 and MLC1 in cardiac injury and dysfunction.
- To elucidate the temporal relationship between MMP-2 activation, MLC1 degradation, and cardiac dysfunction during left anterior descending (LAD) coronary artery occlusion and reperfusion.
Main Methods:
- Isolated rat hearts were subjected to Langendorff perfusion with LAD occlusion for 45 or 90 minutes, followed by reperfusion.
- Cardiac function was assessed by rate-pressure product.
- MMP-2 activity was measured using gelatin zymography, and MLC1 degradation was analyzed.
Main Results:
- Ninety minutes of LAD occlusion significantly impaired cardiac function and led to 60% infarct size upon reperfusion.
- MMP-2 activity increased during both occlusion and reperfusion.
- MLC1 degradation was evident at the end of reperfusion but not occlusion, correlating with increased MMP-2 activity and decreased TIMP-4 levels during reperfusion.
Conclusions:
- MMP-2 activation occurs during ischemia and persists into reperfusion.
- MLC1 degradation is a reperfusion-specific event, mediated by MMP-2.
- A compensatory increase in TIMP-4 during occlusion protects MLC1 from degradation, with this protection lost during reperfusion.
